{"SPADE_UN_13854": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_13854", "Peptide Name": "P1(SARS-CoV (1153-1189))", "Source": "Synthetic construct", "Family": "Coronaviridae", "Gene": "Not found", "Sequence": "GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE", "Sequence Length": 37, "UniProt Entry": ["http://www.uniprot.org/uniprot/P59594"], "Protein Existence": "Not found", "Biological Activity": ["Antimicrobial", "Antiviral"], "Target Organism": "[Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=0.62 ± 0.20 μM);inhibition of SARS-CoV infection in Vero-E6 cells (IC50=3.04 ± 0.06 μM).[Ref.15043961]SARS-CoV:inhibition of the cytopathic effect in Vero E6 cells(IC50~19 μM/L).", "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry", "Cytotoxicity": "[Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM.", "Binding Target": "membrane", "Linear/Cyclic": "Linear", "N-terminal Modification": "Free", "C-terminal Modification": "Free", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C181H302N50O62", "Mass": 4170.63, "PI": 4.62, "Net Charge": -3, "Hydrophobicity": -0.42, "Half Life": "Mammalian:30 hourYeast:>20 hourE.coli:>10 hour", "Mechanism of action": "Binding to the HR1 region and blocking the formation of  a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry.", "Literature": [{"Title": "Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.", "Pubmed ID": "18983873", "Reference": "Antiviral Res. 2009 Jan;81(1)82-7.", "Author": "Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=18983873"}, {"Title": "Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus implications for virus fusogenic mechanism and identification of fusion inhibitors.", "Pubmed ID": "15043961", "Reference": "Lancet. 2004 Mar 20;363(9413)938-47.", "Author": "Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=15043961"}], "Frequent Amino Acids": "ELN", "Absent Amino Acids": "CFHMOPTUW", "Basic Residues": 4, "Acidic Residues": 7, "Hydrophobic Residues": 15, "Polar Residues": 19, "Positive Residues": 4, "Negative Residues": 7, "Similar Sequences": [{"SPADE_ID": "SPADE_UN_13518", "Similarity": 1.0, "Sequence": "DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL"}, {"SPADE_ID": "SPADE_UN_13521", "Similarity": 1.0, "Sequence": "ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL"}, {"SPADE_ID": "SPADE_UN_13554", "Similarity": 1.0, "Sequence": "EISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL"}]}}}